Records containing: Idiopathic Pulmonary Fibrosis
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2022-10-05Investigating Idiopathic Pulmonary Fibrosis in Greece
-
CLINICAL_TRIALS study record update · 2022-10-04Evolution of Lung 18FDG Uptake in Patients With Idiopathic Pulmonary Fibrosis and Receiving Pirfenidone
-
CLINICAL_TRIALS study record update · 2022-10-03Comparison of the 1-min Sit-to-Stand Test to the 6-minute Walk Test in the Respiratory Functional Assessment of Pulmonary Fibrosis: a Cross-over Trial
-
CLINICAL_TRIALS study record update · 2022-09-10129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study
-
CLINICAL_TRIALS study record update · 2022-09-08A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Belumosudil in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2022-08-29Prospective Validation of Cough, Dyspnea, and Quality of Life Questionnaires in Patients With Idiopathic Pulmonary Fibrosis (IPF)
-
CLINICAL_TRIALS study record update · 2022-08-18Efficacy and Safety of Jin-shui Huan-xian Granule in the Treatment of IPF
-
CLINICAL_TRIALS study record update · 2022-07-29A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary Fibrosis
-
CLINICAL_TRIALS study record update · 2022-07-29A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary Fibrosis
-
CLINICAL_TRIALS study record update · 2022-07-27Investigating Significant Health Trends in IPF (INSIGHTS-IPF). Nationwide Prospective Registry.
-
CLINICAL_TRIALS study record update · 2022-07-25Study on TCM Syndrome Classification of Idiopathic Pulmonary Fibrosis Based on Metabolomics
-
CLINICAL_TRIALS study record update · 2022-07-22An Observational Study of Self-monitoring of Spirometry and Symptoms Via the patientMpower App in Patients With Idiopathic Pulmonary Fibrosis
-
CLINICAL_TRIALS study record update · 2022-07-20A Randomized, Double-blind, Multi-center Phase II Clinical Study to Evaluate the Efficacy and Safety of Two Different Dose Groups of AK3280 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Compared to the Placebo Control Group
-
CLINICAL_TRIALS study record update · 2022-07-19An Open Label Study of the Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough
-
CLINICAL_TRIALS study record update · 2022-06-30Cyclophosphamide Added to Corticosteroid in the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Placebo-controlled Randomized Trial
-
CLINICAL_TRIALS study record update · 2022-05-19A Single Center, Open Label Study to Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers
-
CLINICAL_TRIALS study record update · 2022-05-18RESPIRARE - A Phase 2, Randomized, Double-blinded, Placebo-controlled, Efficacy and Safety Study of Cudetaxestat (BLD-0409) Assessed Across Three Dose Ranges With or Without Standard of Care (Nintedanib or Pirfenidone) in Patients With Idiopathic Pulmonary Fibrosis (IPF)
-
CLINICAL_TRIALS study record update · 2022-05-12A Longitudinal, Digital Study Using the Medication Adherence Reasons Scale (MAR-Scale) to Identify the Reasons for Non-adherence to Medications in Rare Disease
-
CLINICAL_TRIALS study record update · 2022-05-05Changes in Impulse Oscillometry Measurements and Outcomes in Idiopathic Pulmonary Fibrosis
-
CLINICAL_TRIALS study record update · 2022-05-05Reliability and Validity of iOS in IPF
-
CLINICAL_TRIALS study record update · 2022-04-29A Phase One-B (1B) Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)
-
CLINICAL_TRIALS study record update · 2022-04-15Health and Quality of Life Assessment Project for Caregivers of Idiopathic Pulmonary Fibrosis Patients
-
CLINICAL_TRIALS study record update · 2022-03-15A Randomized, Double-Blind, Placebo-Controlled Study of Ascending Single and Multiple Doses to Evaluate the Safety, Tolerability, Pharmacokinetics, and Randomized, Open-label，Crossover, Food Effect Study of HEC585 in Healthy Chinese Subjects
-
CLINICAL_TRIALS study record update · 2022-03-07A Randomized, Double-Blind, Placebo-Controlled, Ph 1a, First-in-Man, Single Ascending Dose & Multiple Ascending Dose Safety, Tolerability and PK Study of a Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Healthy Adult Subjects
-
CLINICAL_TRIALS study record update · 2022-02-15A Prospective Observational Registry to Describe the Disease Course and Outcomes of Idiopathic Pulmonary Fibrosis Patients in a Real-world Clinical Setting. PROOF-Registry New and Extended Belgium -Luxembourg